Evidence-based clinical practice guidelines for irritable bowel syndrome 2020

[1]  P. Whorwell,et al.  Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. , 2020, Gastroenterology.

[2]  W. Shih,et al.  Negative Events During Adulthood are Associated With Symptom Severity and Altered Stress Response in Patients With Irritable Bowel Syndrome. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  A. Carrasco-Labra,et al.  AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) , 2019, Gastroenterology.

[4]  A. Carrasco-Labra,et al.  American Gastroenterological Association Guideline on Mild-to-Moderate Ulcerative Colitis on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). , 2019, Gastroenterology.

[5]  D. Schuppan,et al.  Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E. , 2019, Gastroenterology.

[6]  M. Surette,et al.  Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. , 2019, Gastroenterology.

[7]  Jennifer S. Lin,et al.  The Development of Clinical Guidelines and Guidance Statements by the Clinical Guidelines Committee of the American College of Physicians: Update of Methods , 2019, Annals of Internal Medicine.

[8]  P. Moayyedi,et al.  Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis , 2019, Gut.

[9]  Y. Kinoshita,et al.  Eosinophilic gastrointestinal diseases - Pathogenesis, diagnosis, and treatment. , 2019, Allergology international : official journal of the Japanese Society of Allergology.

[10]  Kehu Yang,et al.  Assessment of the Quality and Content of Clinical Practice Guidelines on Irritable Bowel Syndrome Using the AGREE II Instrument , 2019, Digestion.

[11]  P. Higgins,et al.  Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. , 2019, The American journal of gastroenterology.

[12]  M. Camilleri,et al.  Efficacy, long‐term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan , 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[13]  P. Moayyedi,et al.  Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS) , 2019, Journal of the Canadian Association of Gastroenterology.

[14]  G. Mullin,et al.  The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data , 2019, BMC Complementary and Alternative Medicine.

[15]  Justin C.Y. Wu,et al.  Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis , 2019, Therapeutic advances in gastroenterology.

[16]  U. Ghoshal,et al.  Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. , 2019, Gastroenterology.

[17]  H. Matsumoto,et al.  Efficacy of Mirtazapine on Irritable Bowel Syndrome with Anxiety and Depression: A Case Study. , 2018, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[18]  G. Zheng,et al.  Association between SERT insertion/deletion polymorphism and the risk of irritable bowel syndrome: A meta-analysis based on 7039 subjects. , 2018, Gene.

[19]  P. Moayyedi,et al.  Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. , 2018, Gastroenterology.

[20]  F. Azpiroz,et al.  Probiotics in irritable bowel syndrome: Where are we? , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[21]  P. Moayyedi,et al.  Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome , 2018, Alimentary pharmacology & therapeutics.

[22]  E. Zhao,et al.  Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[23]  W. Yeo,et al.  Systematic review with meta‐analysis: The association between post‐traumatic stress disorder and irritable bowel syndrome , 2018, Journal of gastroenterology and hepatology.

[24]  M. Currie,et al.  A randomized controlled and long‐term linaclotide study of irritable bowel syndrome with constipation patients in Japan , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[25]  M. Camilleri,et al.  Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. , 2018, The lancet. Gastroenterology & hepatology.

[26]  L. Hansen,et al.  Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study , 2018, Gut.

[27]  A. Awaisu,et al.  Efficacy and safety of laxatives for chronic constipation in long‐term care settings: A systematic review , 2018, Journal of clinical pharmacy and therapeutics.

[28]  Lingping Zhu,et al.  Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis , 2018, Evidence-based complementary and alternative medicine : eCAM.

[29]  P. Whorwell,et al.  Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidence‐based international consensus , 2018, Alimentary pharmacology & therapeutics.

[30]  N. Ishimura,et al.  Celiac disease in non-clinical populations of Japan , 2018, Journal of Gastroenterology.

[31]  Lin Chang,et al.  FUNCTIONAL BOWEL DISORDERS , 2018, The American Journal of Gastroenterology.

[32]  P. Schoenfeld,et al.  Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis , 2018, The American Journal of Gastroenterology.

[33]  P. Dupont,et al.  Influence of Uncertain Anticipation on Brain Responses to Aversive Rectal Distension in Patients With Irritable Bowel Syndrome , 2017, Psychosomatic medicine.

[34]  N. Waszkiewicz,et al.  Antidepressants for irritable bowel syndrome—A systematic review , 2017, Pharmacological reports : PR.

[35]  M. Camilleri,et al.  Pharmacotherapy for Irritable Bowel Syndrome , 2017, Journal of clinical medicine.

[36]  P. Dupont,et al.  Altered brain and gut responses to corticotropin-releasing hormone (CRH) in patients with irritable bowel syndrome , 2017, Scientific Reports.

[37]  U. Ghoshal,et al.  Mapping of Brain Activations to Rectal Balloon Distension Stimuli in Male Patients with Irritable Bowel Syndrome Using Functional Magnetic Resonance Imaging , 2017, Journal of neurogastroenterology and motility.

[38]  M. Hattori,et al.  Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome , 2017, Digestion.

[39]  M. Camilleri,et al.  Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[40]  T. Kanai,et al.  Colonic dysmotility and morphological abnormality frequently detected in Japanese patients with irritable bowel syndrome , 2017, Intestinal research.

[41]  Lin Lin,et al.  Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials , 2017, PloS one.

[42]  S. Hollon,et al.  Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: A systematic review and meta-analysis. , 2017, Clinical psychology review.

[43]  B. Feng,et al.  Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article , 2017, Anesthesiology and pain medicine.

[44]  C. Lam,et al.  Distinct Abnormalities of Small Bowel and Regional Colonic Volumes in Subtypes of Irritable Bowel Syndrome Revealed by MRI , 2016, The American Journal of Gastroenterology.

[45]  P. Schoenfeld,et al.  Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea , 2016, The American Journal of Gastroenterology.

[46]  M. Mínguez,et al.  Use of polyethylene glycol in functional constipation and fecal impaction. , 2016, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[47]  W. Shih,et al.  Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response , 2016, Psychoneuroendocrinology.

[48]  M. Lomer,et al.  British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). , 2016, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[49]  S. Fukudo,et al.  Dai-Kenchu-To, a Herbal Medicine, Attenuates Colorectal Distention-induced Visceromotor Responses in Rats , 2016, Journal of neurogastroenterology and motility.

[50]  P. Dupont,et al.  Differential Activation in Amygdala and Plasma Noradrenaline during Colorectal Distention by Administration of Corticotropin-Releasing Hormone between Healthy Individuals and Patients with Irritable Bowel Syndrome , 2016, PloS one.

[51]  D. Drossman.  Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. , 2016, Gastroenterology.

[52]  P. Whorwell,et al.  Centrally Mediated Disorders of Gastrointestinal Pain. , 2016, Gastroenterology.

[53]  Xiangfeng Wang,et al.  Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2016, Mayo Clinic proceedings.

[54]  P. Carmeliet,et al.  Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. , 2016, Gastroenterology.

[55]  S. Fukudo,et al.  Associations between Single-Nucleotide Polymorphisms in Corticotropin-Releasing Hormone-Related Genes and Irritable Bowel Syndrome , 2016, PLoS ONE.

[56]  T. Okumura,et al.  Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women. , 2016, Gastroenterology.

[57]  Y. Yamaguchi-Kabata,et al.  Corticotropin-Releasing Hormone Receptor 2 Gene Variants in Irritable Bowel Syndrome , 2016, PloS one.

[58]  T. Okumura,et al.  Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study , 2016, Journal of Gastroenterology.

[59]  L. Turner,et al.  Eluxadoline for Irritable Bowel Syndrome with Diarrhea. , 2016, The New England journal of medicine.

[60]  Cheng-Li Lin,et al.  Irritable Bowel Syndrome Is Associated with an Increased Risk of Dementia: A Nationwide Population-Based Study , 2016, PloS one.

[61]  L. Böhn,et al.  Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. , 2015, Gastroenterology.

[62]  M. Camilleri,et al.  Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis , 2015, Gut.

[63]  Lin Lin,et al.  Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis , 2015, PloS one.

[64]  C. Manichanh,et al.  Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome , 2015, Scientific Reports.

[65]  R. Spiller,et al.  Irritable bowel syndrome , 2015, Nature Reviews Disease Primers.

[66]  A. Ford,et al.  Systematic review with meta‐analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea , 2015, Alimentary pharmacology & therapeutics.

[67]  J. Guardiola,et al.  Randomised clinical trial: colestyramine vs. hydroxypropyl cellulose in patients with functional chronic watery diarrhoea , 2015, Alimentary pharmacology & therapeutics.

[68]  R. Spiller,et al.  A meta‐analysis of immunogenetic Case–Control Association Studies in irritable bowel syndrome , 2015, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[69]  S. Kim,et al.  Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double‐blind, placebo‐controlled, multicenter, phase II trial , 2015, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[70]  E. Mayer,et al.  Serotonin Transporter Gene Polymorphism Modulates Activity and Connectivity within an Emotional Arousal Network of Healthy Men during an Aversive Visceral Stimulus , 2015, PloS one.

[71]  A. Zinsmeister,et al.  Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea‐predominant irritable bowel syndrome , 2015, Alimentary pharmacology & therapeutics.

[72]  Jacob E. Kurlander,et al.  A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS , 2015, The American Journal of Gastroenterology.

[73]  G. Ringström,et al.  Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. , 2015, World journal of gastroenterology.

[74]  L. Brandt,et al.  Is Fecal Microbiota Transplantation the Answer for Irritable Bowel Syndrome? A Single-Center Experience , 2014, The American Journal of Gastroenterology.

[75]  P. Moayyedi,et al.  Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis , 2014, The American Journal of Gastroenterology.

[76]  P. Moayyedi,et al.  The Effect of Fiber Supplementation on Irritable Bowel Syndrome: A Systematic Review and Meta-analysis , 2014, The American Journal of Gastroenterology.

[77]  H. Zhang,et al.  Efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety. , 2014, World journal of gastroenterology.

[78]  N. Bunnett.  Neuro‐humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract , 2014, The Journal of physiology.

[79]  S. Fukudo,et al.  Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[80]  M. Camilleri,et al.  Systematic review with meta‐analysis: highly selective 5‐HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation , 2014, Alimentary pharmacology & therapeutics.

[81]  T. Oka,et al.  Effects of Kampo on functional gastrointestinal disorders , 2014, BioPsychoSocial Medicine.

[82]  F. Sung,et al.  Irritable bowel syndrome correlates with increased risk of Parkinson’s disease in Taiwan , 2014, European Journal of Epidemiology.

[83]  I. Hall,et al.  A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea , 2013, Gut.

[84]  S. Fukudo.  Stress and visceral pain: Focusing on irritable bowel syndrome , 2013, PAIN®.

[85]  Y. Jeen,et al.  [Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study]. , 2013, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[86]  R. Khanna,et al.  Peppermint Oil for the Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis , 2013, Journal of clinical gastroenterology.

[87]  M. Daly,et al.  Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts , 2013, Gut.

[88]  A. Zinsmeister,et al.  Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[89]  T. Timpka,et al.  Patients with irritable bowel syndrome are more burdened by co-morbidity and worry about serious diseases than healthy controls- eight years follow-up of IBS patients in primary care , 2013, BMC Public Health.

[90]  J. Almenoff,et al.  Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. , 2013, Gastroenterology.

[91]  V. Verhasselt,et al.  Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation , 2013, Gut.

[92]  R. Chapman,et al.  Randomized Clinical Trial: Macrogol/PEG 3350 Plus Electrolytes for Treatment of Patients With Constipation Associated With Irritable Bowel Syndrome , 2013, The American Journal of Gastroenterology.

[93]  T. Kutlu,et al.  The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment , 2013, Journal of neurogastroenterology and motility.

[94]  H. Mushiake,et al.  Altered cognitive function of prefrontal cortex during error feedback in patients with irritable bowel syndrome, based on FMRI and dynamic causal modeling. , 2012, Gastroenterology.

[95]  A. Ford,et al.  Prevalence of Symptoms Meeting Criteria for Irritable Bowel Syndrome in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2012, The American Journal of Gastroenterology.

[96]  S. Fukudo,et al.  Corticotropin-Releasing Hormone Receptor 1 Gene Variants in Irritable Bowel Syndrome , 2012, PloS one.

[97]  A. Lembo,et al.  Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS , 2012, Alimentary pharmacology & therapeutics.

[98]  A. Ford,et al.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[99]  S. Ishihara,et al.  Prevalence of organic colonic lesions in patients meeting Rome III criteria for diagnosis of IBS: a prospective multi-center study utilizing colonoscopy , 2012, Journal of Gastroenterology.

[100]  W. Chey,et al.  Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation , 2012, Alimentary pharmacology & therapeutics.

[101]  J. Tack,et al.  Colonic Transit Time and IBS Symptoms: What's the Link? , 2012, The American Journal of Gastroenterology.

[102]  L. Öhman,et al.  Altered Levels of Fecal Chromogranins and Secretogranins in IBS: Relevance for Pathophysiology and Symptoms? , 2012, The American Journal of Gastroenterology.

[103]  N. Talley,et al.  The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study , 2012, Gut.

[104]  W. Chey,et al.  The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis , 2012, The American Journal of Gastroenterology.

[105]  P. Whorwell,et al.  Severity in Irritable Bowel Syndrome: A Rome Foundation Working Team Report , 2011, The American Journal of Gastroenterology.

[106]  K. Whelan,et al.  Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. , 2011, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[107]  N. D. de Wit,et al.  Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. , 2011, The Cochrane database of systematic reviews.

[108]  S. Fukudo,et al.  Effect of 5‐HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[109]  B. Kim,et al.  Trimebutine as a modulator of gastrointestinal motility , 2011, Archives of pharmacal research.

[110]  M. Kamm,et al.  Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[111]  M. Hongo,et al.  Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo‐controlled and dose‐finding study , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[112]  M. Simrén,et al.  Physical Activity Improves Symptoms in Irritable Bowel Syndrome: A Randomized Controlled Trial , 2011, The American Journal of Gastroenterology.

[113]  M. Camilleri,et al.  Symptomatic overlap between irritable bowel syndrome and microscopic colitis. , 2011, Inflammatory bowel diseases.

[114]  B. Jiang,et al.  Organic colonic lesions in 3,332 patients with suspected irritable bowel syndrome and lacking warning signs, a retrospective case–control study , 2011, International Journal of Colorectal Disease.

[115]  K. Tominaga,et al.  Differences between risk factors among irritable bowel syndrome subtypes in Japanese adults , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[116]  H. Sørensen,et al.  Irritable bowel syndrome and risk of colorectal cancer: a Danish nationwide cohort study , 2011, British Journal of Cancer.

[117]  W. Chey,et al.  Rifaximin therapy for patients with irritable bowel syndrome without constipation. , 2011, The New England journal of medicine.

[118]  B. Cash,et al.  The Incidence and Gastrointestinal Infectious Risk of Functional Gastrointestinal Disorders in a Healthy US Adult Population , 2011, The American Journal of Gastroenterology.

[119]  A. Zinsmeister,et al.  Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. , 2010, Gastroenterology.

[120]  M. Forsting,et al.  Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. , 2010, Gastroenterology.

[121]  Lin Chang,et al.  Diagnosis and management of IBS , 2010, Nature Reviews Gastroenterology &Hepatology.

[122]  B. Spiegel,et al.  Meta‐analysis: do irritable bowel syndrome symptoms vary between men and women? , 2010, Alimentary pharmacology & therapeutics.

[123]  M. Hongo,et al.  Effect of Autogenic Training on General Improvement in Patients with Irritable Bowel Syndrome: A Randomized Controlled Trial , 2010, Applied psychophysiology and biofeedback.

[124]  O. Nielsen,et al.  The safety of osmotically acting cathartics in colonic cleansing , 2010, Nature Reviews Gastroenterology &Hepatology.

[125]  P. Shekelle,et al.  The Development of Clinical Practice Guidelines and Guidance Statements of the American College of Physicians: Summary of Methods , 2010, Annals of Internal Medicine.

[126]  Eun Soo Kim,et al.  Colonoscopy as an adjunctive method for the diagnosis of irritable bowel syndrome: Focus on pain perception , 2010, Journal of gastroenterology and hepatology.

[127]  Kirsten Tillisch,et al.  Regional gray matter density changes in brains of patients with irritable bowel syndrome. , 2010, Gastroenterology.

[128]  G. Wall,et al.  Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. , 2010, Clinical therapeutics.

[129]  J. Belsey,et al.  Systematic review and meta analysis: polyethylene glycol in adults with non‐organic constipation , 2010, International journal of clinical practice.

[130]  K. Tominaga,et al.  Prevalence of overlaps between GERD, FD and IBS and impact on health‐related quality of life , 2010, Journal of gastroenterology and hepatology.

[131]  M. Pimentel.  An Evidence-Based Treatment Algorithm for IBS Based on a Bacterial/SIBO Hypothesis: Part 2 , 2010, The American Journal of Gastroenterology.

[132]  A. Zinsmeister,et al.  Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[133]  K. Davis,et al.  Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. , 2010, Gastroenterology.

[134]  A. Garg,et al.  Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. , 2010, Gastroenterology.

[135]  A. Attili,et al.  Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial. , 2010, European review for medical and pharmacological sciences.

[136]  M. Kamm,et al.  Multicenter, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Sodium Picosulfate in Patients With Chronic Constipation , 2010, The American Journal of Gastroenterology.

[137]  D. Drossman.  Beyond Tricyclics: New Ideas for Treating Patients With Painful and Refractory Functional Gastrointestinal Symptoms , 2009, The American Journal of Gastroenterology.

[138]  S. Fukudo,et al.  Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[139]  R. A’Hern,et al.  Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea‐predominant irritable bowel syndrome , 2009, Alimentary pharmacology & therapeutics.

[140]  Kazuhiko Yanai,et al.  Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention , 2009, NeuroImage.

[141]  P. Whorwell,et al.  Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial , 2009, BMJ : British Medical Journal.

[142]  B. P. Brennan,et al.  Duloxetine in the treatment of irritable bowel syndrome: an open‐label pilot study , 2009, Human psychopharmacology.

[143]  R. Moss‐Morris,et al.  A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care , 2009, Psychological Medicine.

[144]  P. Moayyedi,et al.  Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. , 2009, Archives of internal medicine.

[145]  B. Neri,et al.  Use of serum biomarkers in a diagnostic test for irritable bowel syndrome , 2009, Alimentary pharmacology & therapeutics.

[146]  E. Quigley,et al.  Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics). , 2009, Journal of gastrointestinal and liver diseases : JGLD.

[147]  G. Gibson,et al.  Clinical trial: the effects of a trans‐galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome , 2009, Alimentary pharmacology & therapeutics.

[148]  D. Drossman,et al.  Atypical Antipsychotic Quetiapine in the Management of Severe Refractory Functional Gastrointestinal Disorders , 2009, Digestive Diseases and Sciences.

[149]  Rafael Perera,et al.  A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome , 2009, BMC gastroenterology.

[150]  D. Tester,et al.  Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[151]  P. Moayyedi,et al.  The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review , 2008, Gut.

[152]  P. Moayyedi,et al.  Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis , 2008, BMJ : British Medical Journal.

[153]  T. Timpka,et al.  Self-Reported Use of Pharmaceuticals Among Patients With Irritable Bowel Syndrome in Primary Care , 2008, Journal of managed care pharmacy : JMCP.

[154]  D. Drossman,et al.  Contributions of Pain Sensitivity and Colonic Motility to IBS Symptom Severity and Predominant Bowel Habits , 2008, The American Journal of Gastroenterology.

[155]  R. Spiller.  Review article: probiotics and prebiotics in irritable bowel syndrome , 2008, Alimentary pharmacology & therapeutics.

[156]  M. Camilleri,et al.  Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[157]  M. Hongo,et al.  A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome , 2008, Scandinavian journal of gastroenterology.

[158]  P. Whorwell,et al.  Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. , 2007, The Cochrane database of systematic reviews.

[159]  W. Chey,et al.  The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review , 2007, The American Journal of Gastroenterology.

[160]  Lin Chang,et al.  GASTROENTEROLOGY CLINICS OF NORTH AMERICA Irritable Bowel Syndrome : Current Approach to Symptoms , Evaluation , and Treatment , 2022 .

[161]  M. Thabane,et al.  Systematic review and meta‐analysis: the incidence and prognosis of post‐infectious irritable bowel syndrome , 2007, Alimentary pharmacology & therapeutics.

[162]  S. Gordon,et al.  A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of 0.5 mg and 1 mg Alosetron in Women With Severe Diarrhea-predominant IBS , 2007, The American Journal of Gastroenterology.

[163]  E. Blanchard,et al.  How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial. , 2007, Gastroenterology.

[164]  B. Spiegel,et al.  Systematic review: the prevalence of suicidal behaviour in patients with chronic abdominal pain and irritable bowel syndrome , 2007, Alimentary pharmacology & therapeutics.

[165]  M. Camilleri,et al.  Symptomatic overlap between irritable bowel syndrome and microscopic colitis , 2007 .

[166]  Khek Yu Ho,et al.  Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls , 2006, Pain.

[167]  M. Pimentel,et al.  The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome , 2006, Annals of Internal Medicine.

[168]  M. Içer,et al.  Ultrasonographic evaluation of gallbladder functions in patients with irritable bowel syndrome , 2006, Journal of gastroenterology and hepatology.

[169]  K. Haruma,et al.  [Ultrasonographic assessment of sigmoid colon in patients with irritable bowel syndrome]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[170]  M. Pimentel,et al.  Neomycin Improves Constipation-Predominant Irritable Bowel Syndrome in a Fashion That Is Dependent on the Presence of Methane Gas: Subanalysis of a Double-Blind Randomized Controlled Study , 2006, Digestive Diseases and Sciences.

[171]  Á. Lanas,et al.  Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome – a European perspective , 2006, Alimentary pharmacology & therapeutics.

[172]  L. Houghton,et al.  Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective , 2006, Alimentary pharmacology & therapeutics.

[173]  L. Marzio,et al.  Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. , 2006, Digestive and Liver Disease.

[174]  P. Scully,et al.  Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? , 2006, Gastroenterology.

[175]  H. Keleş,et al.  Evaluation of gallbladder motility in patients with irritable bowel syndrome. , 2005, Swiss medical weekly.

[176]  D. Drossman,et al.  A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. , 2005, Gastroenterology.

[177]  W. Chey,et al.  Long-Term Safety and Efficacy of Alosetron in Women with Severe Diarrhea-Predominant Irritable Bowel Syndrome , 2004, The American Journal of Gastroenterology.

[178]  S. Dolwani,et al.  Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology , 2004, Alimentary pharmacology & therapeutics.

[179]  M. Hongo,et al.  Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome , 2004, Gut.

[180]  W. Whitehead,et al.  Patients and Nonconsulters with Irritable Bowel Syndrome Reporting a Parental History of Bowel Problems Have More Impaired Psychological Distress , 2004, Digestive Diseases and Sciences.

[181]  H. El‐Serag,et al.  Natural history of irritable bowel syndrome , 2004 .

[182]  Ke-min Chen,et al.  Functional brain imaging in irritable bowel syndrome with rectal balloon-distention by using fMRI. , 2003, World journal of gastroenterology.

[183]  A. Wald.  Is Chronic Use of Stimulant Laxatives Harmful to the Colon? , 2003, Journal of clinical gastroenterology.

[184]  M. Mandelkern,et al.  The effect of the 5‐HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients , 2002, Alimentary pharmacology & therapeutics.

[185]  W. Whitehead,et al.  Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? , 2002, Gastroenterology.

[186]  Shara I. Feld,et al.  Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. , 2001, Gastroenterology.

[187]  P. Jhingran,et al.  Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome , 2001, American Journal of Gastroenterology.

[188]  M. Camilleri,et al.  A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. , 2001, Archives of internal medicine.

[189]  I. Wiklund,et al.  Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials , 2001, Alimentary pharmacology & therapeutics.

[190]  T. Poynard,et al.  Meta‐analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome , 2001, Alimentary pharmacology & therapeutics.

[191]  A. Mangel,et al.  Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome , 2001, American Journal of Gastroenterology.

[192]  A. Kilbourne,et al.  The impact of irritable bowel syndrome on health-related quality of life. , 2000, Gastroenterology.

[193]  M. Camilleri,et al.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial , 2000, The Lancet.

[194]  D. Drossman,et al.  Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonist , 1999, Alimentary pharmacology & therapeutics.

[195]  A. Ishige,et al.  Effects of Keishi-ka-shakuyaku-to (Gui-Zhi-Jia-Shao-Yao-Tang) on diarrhea and small intestinal movement. , 1999, Biological & pharmaceutical bulletin.

[196]  A. Francavilla,et al.  Otilonium bromide in irritable bowel syndrome: a double‐blind, placebo‐controlled, 15‐week study , 1998, Alimentary pharmacology & therapeutics.

[197]  M. Hongo,et al.  Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome , 1998, Gut.

[198]  A. Ishige,et al.  The effects of Hange-shashin-to on the content of prostaglandin E2 and water absorption in the large intestine of rats. , 1997, Biological & pharmaceutical bulletin.

[199]  M. Delvaux,et al.  Trimebutine: Mechanism of Action, Effects on Gastrointestinal Function and Clinical Results , 1997, The Journal of international medical research.

[200]  N. Talley,et al.  Predictors of health care seeking for irritable bowel syndrome: a population based study , 1997, Gut.

[201]  M. Vatn,et al.  A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. , 1996, Scandinavian journal of gastroenterology.

[202]  U. Malt,et al.  A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. , 1996, Scandinavian journal of gastroenterology.

[203]  G. Gasbarrini,et al.  Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. , 1995, Scandinavian journal of gastroenterology.

[204]  B. Mory,et al.  Meta‐analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome , 1994, Alimentary pharmacology & therapeutics.

[205]  E. Blanchard,et al.  Relaxation training as a treatment for irritable bowel syndrome , 1993, Biofeedback and self-regulation.

[206]  P. Toskes,et al.  Calcium polycarbophil compared with placebo in irritable bowel syndrome , 1993, Alimentary pharmacology & therapeutics.

[207]  W. Whitehead,et al.  Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. , 1992, Gut.

[208]  E. Guthrie.  Brief Psychotherapy with Patients with Refractory Irritable Bowel Syndrome , 1991 .

[209]  C. Tanaka,et al.  Dual effect of trimebutine on contractility of the guinea pig ileum via the opioid receptors. , 1991, Gastroenterology.

[210]  G. Bensi,et al.  Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. , 1990, Gut.

[211]  D. Jewell,et al.  Food intolerance and the irritable bowel syndrome. , 1989, Gut.

[212]  D. Drossman,et al.  Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. , 1988, Gastroenterology.

[213]  E. Blanchard,et al.  A multi-component treatment for irritable bowel syndrome , 1987 .

[214]  S. Fukudo,et al.  Colonic motility, autonomic function, and gastrointestinal hormones under psychological stress on irritable bowel syndrome. , 1987, The Tohoku journal of experimental medicine.

[215]  P. Whorwell,et al.  CONTROLLED TRIAL OF HYPNOTHERAPY IN THE TREATMENT OF SEVERE REFRACTORY IRRITABLE-BOWEL SYNDROME , 1984, The Lancet.

[216]  A. Gupta,et al.  Different therapeutic regimens in irritable bowel syndrome. , 1984, The Journal of the Association of Physicians of India.

[217]  N. Read,et al.  Oral domperidone: double blind comparison with placebo in irritable bowel syndrome. , 1983, Gut.

[218]  J. Svedlund,et al.  CONTROLLED STUDY OF PSYCHOTHERAPY IN IRRITABLE BOWEL SYNDROME , 1983, The Lancet.

[219]  M. F. Brian E. Lacy PhD,et al.  Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis , 2018, The American Journal of Gastroenterology.

[220]  P. Valle,et al.  Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. , 2018, The lancet. Gastroenterology & hepatology.

[221]  R. Spiller,et al.  Bowel Disorders. , 2016, Gastroenterology.

[222]  박효진.  Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial , 2015 .

[223]  Masahiro Yoshida,et al.  JSGE Clinical Practice Guidelines 2014: standards, methods, and process of developing the guidelines , 2014, Journal of Gastroenterology.

[224]  F. Sung,et al.  Association between irritable bowel syndrome and colorectal cancer: a nationwide population-based study. , 2014, European journal of internal medicine.

[225]  K. Sugano,et al.  Evidence-based clinical practice guidelines for irritable bowel syndrome , 2014, Journal of Gastroenterology.

[226]  Kirsten Tillisch,et al.  Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. , 2011, Gastroenterology.

[227]  W. Whitehead,et al.  Therapeutic mechanisms of a mindfulness-based treatment for IBS: effects on visceral sensitivity, catastrophizing, and affective processing of pain sensations , 2011, Journal of Behavioral Medicine.

[228]  D. Katzka.  How Does Cognitive Behavior Therapy for Irritable Bowel Syndrome Work? A Mediational Analysis of a Randomized Clinical Trial , 2008 .

[229]  S. Hanauer.  The role of loperamide in gastrointestinal disorders. , 2008, Reviews in gastroenterological disorders.

[230]  J. Barkin.  The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial , 2007 .

[231]  D. Dumitrascu,et al.  The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome. , 2006, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[232]  H. El‐Serag,et al.  Systemic review: Natural history of irritable bowel syndrome. , 2004, Alimentary pharmacology & therapeutics.

[233]  Yosuke Kawasaki,et al.  [Irritable bowel syndrome(IBS)]. , 2003, Ryoikibetsu shokogun shirizu.

[234]  M. Wallander,et al.  Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. , 2000, Scandinavian journal of gastroenterology.

[235]  G Shaw,et al.  Stress management for irritable bowel syndrome: a controlled trial. , 1991, Digestion.

[236]  N. Hovdenak.  Loperamide treatment of the irritable bowel syndrome. , 1987, Scandinavian journal of gastroenterology. Supplement.

[237]  A. Nielsen,et al.  Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. , 1987, Scandinavian journal of gastroenterology. Supplement.

[238]  J. Fielding.  Domperidone treatment in the irritable bowel syndrome. , 1982, Digestion.

[239]  K. Lüttecke.  A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. , 1980, Current medical research and opinion.